Trial Profile
Korean Post-marketing Surveillance for Xeljanz(Registered) in Rheumatoid Arthritis and Psoriatic Arthritis Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Sep 2022
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Pfizer
- 12 Aug 2022 Status changed from recruiting to completed.
- 01 Jun 2022 Planned End Date changed from 26 Apr 2022 to 26 Jun 2022.
- 01 Jun 2022 Planned primary completion date changed from 26 Apr 2022 to 26 Jun 2022.